News Listing

OBN Awards 2021 – Winners Recognised at the Life Sciences Industry’s Event on 25 November 2021

Abingdon, UK, Friday 26 November: – OBN (UK) Ltd., the membership organisation that supports the life sciences industry, is delighted to announce the winners of the 2021 OBN Awards, presented at the Ashmolean Museum on Thursday 25 November. 

The Awards, which are in their 13th year, shine a light ...


Drawing upon over 30-years’ experience of serving the glycobiology research community - AMSBIO has established a comprehensive portfolio of high-quality reagents including unique ranges of antibodies, lectins, enzymes, assay kits and standards, backed by in-depth technical support.

Dr William Hadlington-Booth, Glycobiology product manager commented "To maintain our global reputation as the ...

Biosynth Carbosynth

Antimicrobials include antibiotics, antifungals, antivirals and antiprotozoal agents. Focussing on antibiotics, this brochure reviews the modes of action and resistance of antibiotics, and discusses the important role they play in recombinant protein production.

Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today the start of a Phase 1 trial of OVM-200 with the first patient being treated at the prestigious Sarah Cannon Research Institute in London. The vaccine uses OVM's novel platform technology based on recombinant overlapping peptides.

University of Birmingham

Birmingham, UK, 9th November 2021 / Sciad Newswire / Birmingham Biotech Ltd, an innovator in diagnostic tests, protective nasal sprays and mobile medical facilities, and the University of Birmingham have signed a licensing agreement to commercialise a novel anti-viral nasal spray that protects against COVID-19.

The Oxford Trust

Nine new early-stage science and technology start-up businesses have taken space in The Oxford Trust’s two innovation centres during Autumn, as Oxford continued to see strong demand from businesses needing R&D labs, technical workspace and flexible office space.

OBN, the membership organisation supporting the UK’s innovative life sciences companies, announces today that Dr John Harris will retire as CEO on 30th April 2022, after leading the organisation to achieve significant growth over the last 6 years.

KKR, a leading global investment firm, and Biosynth Carbosynth, a leading life sciences reagents, custom synthesis and manufacturing services company, announce today that KKR has agreed to acquire Biosynth Carbosynth from Armira and CEO Dr. Urs Spitz. Dr. Spitz and senior managers of the company will retain a significant ownership stake and will continue to lead the company as it embarks on its ...

Research published on Tuesday 2 November has demonstrated the feasibility of mass producing customised respiratory protection for healthcare workers with a comfortable close-fitting seal, that is suitable for nearly 90% of face shapes and sizes. 

AMSBIO report that researchers from the Medical University of Vienna (Austria), have used Lipidure® - CM5206 to coat channels in their novel microfluidic devices, to prevent cell adhesion.

The aim of the research by the Medical University of Vienna was to create physiological-relevant in vitro tissue models that offer better predictability and the potential to improve drug screening outcomes in ...